MGNX vs OSUR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MGNX exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe deterioration across all financial health dimensions. While the company shows explosive revenue growth (113% YoY) and maintains a strong liquidity position (Current Ratio 5.10), it suffers from negative gross margins and a consistent track record of missing earnings estimates. The recent 1-year price surge appears decoupled from fundamental value, as the company remains deeply unprofitable with a catastrophic ROE of -86.94%.
OSUR presents a stark contrast between a fortress-like balance sheet and a deteriorating business model. While the Piotroski F-Score of 6/9 indicates stable financial health and the company maintains exceptional liquidity (Current Ratio 6.58) with negligible debt, the operational metrics are alarming. Revenue has contracted by 28.5% YoY, and profit margins are deeply negative at -59.76%. Despite trading at a significant discount to book value (P/B 0.67), the lack of growth and consistent earnings misses suggest a value trap.
Compare Another Pair
Related Comparisons
MGNX vs OSUR: Head-to-Head Comparison
This page compares MacroGenics, Inc. (MGNX) and OraSure Technologies, Inc. (OSUR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.